➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Baxter
McKinsey
AstraZeneca
Mallinckrodt

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 208383


Email this page to a colleague

« Back to Dashboard

NDA 208383 describes BEVYXXA, which is a drug marketed by Portola Pharms Inc and is included in one NDA. There are five patents protecting this drug. Additional details are available on the BEVYXXA profile page.

The generic ingredient in BEVYXXA is betrixaban. Additional details are available on the betrixaban profile page.
Summary for 208383
Tradename:BEVYXXA
Applicant:Portola Pharms Inc
Ingredient:betrixaban
Patents:5
Formulation / Manufacturing:see details
DrugPatentWatch® Estimated Generic Entry Opportunity Date for 208383
Generic Entry Date for 208383*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:CAPSULE;ORALStrength40MG
Approval Date:Jun 23, 2017TE:RLD:Yes
Regulatory Exclusivity Expiration:Jun 23, 2022
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:⤷  Try it FreePatent Expiration:Nov 8, 2026Product Flag?Substance Flag?YDelist Request?
Patent:⤷  Try it FreePatent Expiration:Mar 29, 2031Product Flag?YSubstance Flag?Delist Request?
Patented Use:INHIBITING COAGULATION

Expired US Patents for NDA 208383

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-002 Jun 23, 2017 ⤷  Try it Free ⤷  Try it Free
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-001 Jun 23, 2017 ⤷  Try it Free ⤷  Try it Free
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-001 Jun 23, 2017 ⤷  Try it Free ⤷  Try it Free
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-002 Jun 23, 2017 ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Express Scripts
Medtronic
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.